Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 496283
                    [Title] => Small pharma firms not happy with Maximum Drug Retail Price
                    [Summary] => 
The implementation of the Maximum Drug Retail Price (MDRP) provision of the Cheaper Medicines Act may have the unexpected consequences of once again favoring multinational pharmaceutical companies and squeezing the smaller domestic pharma firms.
                    [DatePublished] => 2009-08-17 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 1805266
                    [AuthorName] => Marianne V. Go
                    [SectionName] => Business
                    [SectionUrl] => business
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 458302
                    [Title] => Pascual Laboratories eyes P4-billion sales for this year
                    [Summary] => 
Pascual Laboratories, Inc. expects to post P4 billion in sales this year, while its wholly-owned subsidiary Pharex Health Corp. is expecting an equally robust sales of P1.5 billion, company chairman Abrahan F. Pascual said.
                    [DatePublished] => 2009-04-18 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 1805266
                    [AuthorName] => Marianne V. Go
                    [SectionName] => Business
                    [SectionUrl] => business
                    [URL] => 
                )

        )

)

PASCUAL LABORATORIES AND PHAREX

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 496283
                    [Title] => Small pharma firms not happy with Maximum Drug Retail Price
                    [Summary] => 
The implementation of the Maximum Drug Retail Price (MDRP) provision of the Cheaper Medicines Act may have the unexpected consequences of once again favoring multinational pharmaceutical companies and squeezing the smaller domestic pharma firms.
                    [DatePublished] => 2009-08-17 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 1805266
                    [AuthorName] => Marianne V. Go
                    [SectionName] => Business
                    [SectionUrl] => business
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 458302
                    [Title] => Pascual Laboratories eyes P4-billion sales for this year
                    [Summary] => 
Pascual Laboratories, Inc. expects to post P4 billion in sales this year, while its wholly-owned subsidiary Pharex Health Corp. is expecting an equally robust sales of P1.5 billion, company chairman Abrahan F. Pascual said.
                    [DatePublished] => 2009-04-18 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 1805266
                    [AuthorName] => Marianne V. Go
                    [SectionName] => Business
                    [SectionUrl] => business
                    [URL] => 
                )

        )

)

abtest

Small pharma firms not happy with Maximum Drug Retail Price

By Marianne V. Go | August 17, 2009 - 12:00am

The implementation of the Maximum Drug Retail Price (MDRP) provision of the Cheaper Medicines Act may have the unexpected consequences of once again favoring multinational pharmaceutical companies and squeezing the...

Business

Pascual Laboratories eyes P4-billion sales for this year

By Marianne V. Go | April 18, 2009 - 12:00am

Pascual Laboratories, Inc. expects to post P4 billion in sales this year, while its wholly-owned subsidiary Pharex Health Corp. is expecting an equally robust sales of P1.5 billion, company chairman Abrahan F. Pascual...

Business